BRCA2 and neoplasm: Importantly in 5 patients for whom tumor pathogenic variant analysis was non-contributive, NGS on cftDNA from ascites was informative and uncovered one pathogenic variant of BRCA2 with obvious immediate implications for germline testing and treatment.